Retatrutide Dosage Calculator: Reconstitution and Units
To calculate retatrutide dosage, divide your target dose (mg) by the vial concentration. Concentration = vial mg ÷ diluent mL. For a 10 mg vial with 2 mL BAC water: concentration is 5 mg/mL. A 2 mg dose equals 0.4 mL (40 U-100 units) on a standard insulin syringe.
Keep exploring this topic
Explore the Retatrutide research cluster
Use these connected calculators, guides, timelines, and comparisons to move from measurement math to broader research context.
Example Retatrutide Dosage Table
Common vial and BAC water combinations with calculated concentration, draw volume, and U-100 syringe units. For education only — verify your vial label before use.
| Vial (mg) | BAC water (mL) | Concentration | Dose (mg) | Draw (mL) | U-100 units |
|---|---|---|---|---|---|
| 10 mg | 2 mL | 5 mg/mL | 1 mg | 0.2 mL | 20 units |
| 10 mg | 2 mL | 5 mg/mL | 2 mg | 0.4 mL | 40 units |
| 10 mg | 2 mL | 5 mg/mL | 5 mg | 1 mL | 100 units |
| 10 mg | 5 mL | 2 mg/mL | 2 mg | 1 mL | 100 units |
How to Calculate Retatrutide Dosage
Three steps convert any vial and BAC water combination into the exact volume to draw on a U-100 insulin syringe.
Step 1 — Calculate concentration (mg/mL)
Divide the total peptide in the vial (mg) by the volume of BAC water you added (mL). For example: a 5 mg Retatrutide vial reconstituted with 2 mL BAC water gives 5 ÷ 2 = 2.5 mg/mL.Step 2 — Calculate draw volume (mL)
Divide your target dose (mg) by the concentration (mg/mL). For a 0.5 mg dose at 2.5 mg/mL: 0.5 ÷ 2.5 = 0.2 mL. This is the exact volume to draw into the syringe.Step 3 — Convert to U-100 syringe units
Multiply the draw volume (mL) by 100. For 0.2 mL: 0.2 × 100 = 20 U-100 units. Read this number on the unit markings of a standard insulin syringe.
Dosage Formula
Concentration formula
Concentration (mg/mL) = Vial mg ÷ BAC water mLDraw volume formula
Draw volume (mL) = Dose (mg) ÷ Concentration (mg/mL)U-100 syringe units
U-100 units = Draw volume (mL) × 100These three formulas apply to any Retatrutide vial, regardless of size. U-100 is the standard insulin-syringe scale: 100 units = 1 mL.
Retatrutide Calculator Tool
Enter your vial strength, BAC water volume, and target dose below. The calculator outputs concentration (mg/mL), draw volume (mL), and U-100 units. Educational and research use only.
Example Retatrutide Calculations
Step-by-step worked examples using common vial sizes. Results are for illustrating the math only.
10 mg vial + 2 mL BAC water, 2 mg dose
- Vial: 10 mg | BAC water: 2 mL | Target dose: 2 mg
- Concentration: 10 ÷ 2 = 5 mg/mL
- Draw volume: 2 ÷ 5 = 0.4 mL
- U-100 units: 0.4 × 100 = 40 units
10 mg vial + 5 mL BAC water, 2 mg dose
- Vial: 10 mg | BAC water: 5 mL | Target dose: 2 mg
- Concentration: 10 ÷ 5 = 2 mg/mL
- Draw volume: 2 ÷ 2 = 1 mL
- U-100 units: 1 × 100 = 100 units
Retatrutide Reconstitution Guide
Retatrutide research vials are typically supplied as lyophilised powder. Reconstitute with bacteriostatic water:
- Swab both stoppers with alcohol.
- Draw desired BAC water volume; inject slowly along vial wall.
- Gently swirl until dissolved. Solution should be clear.
- Store refrigerated. Do not freeze.
Retatrutide (LY3437943) is an investigational triple-agonist (GLP-1, GIP, glucagon) and is not an approved therapy. All use is research only.
Frequently Asked Questions
How do I calculate retatrutide draw volume?
Divide your dose (mg) by the concentration (mg/mL). For a 10 mg vial + 2 mL BAC: 5 mg/mL. For a 2 mg dose: 2 ÷ 5 = 0.4 mL = 40 U-100 units.
What are U-100 syringe units?
U-100 is the standard scale for insulin syringes. 100 units = 1.0 mL. That means 10 units = 0.1 mL, 50 units = 0.5 mL. Multiply any draw volume in mL by 100 to get the U-100 units reading.
Do I need to recalculate if I change the amount of BAC water?
Yes. Changing BAC water volume changes the concentration (mg/mL), which changes the draw volume for the same mg dose. Always recalculate using: concentration = vial mg ÷ BAC water mL, then draw volume = dose mg ÷ concentration.
What is retatrutide?
Retatrutide (LY3437943) is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) studied for obesity and metabolic outcomes. It is not an approved therapy in most regions.
Learn More
Research review and sources
Primary references and supporting sources
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial — Primary phase 2 obesity trial that informs current efficacy and tolerability context.
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial — Phase 2a liver-disease trial that adds human metabolic and safety context.
Full Calculator + Protocol Tracker
The PeptideUniv app includes the full reconstitution calculator, dosing schedules, cycle tracker, and reminders — all in one place.
Open full calculator → · Start free trial →For educational and research purposes only. Not medical advice. Consult a licensed healthcare professional before making any medical or health-related decisions.
